Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity
As published in Science , the new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations.
- As published in Science , the new target was found by sequencing nearly 650,000 people and identifying individuals with rare protective mutations.
- "As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic."
- "We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders.
- Worldwide the prevalence of obesity has more than tripled since 1975, and approximately 650 million adults are estimated to live with obesity today.